David Buck
Stock Analyst at B. Riley Securities
(0.25)
# 4,169
Out of 4,876 analysts
14
Total ratings
21.43%
Success rate
-27.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Buck
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNOV MediciNova | Assumes: Buy | $22 | $1.30 | +1,592.31% | 2 | Mar 25, 2019 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $68 → $65 | $31.16 | +108.60% | 3 | Nov 12, 2018 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $219 → $190 | $106.90 | +77.74% | 4 | Nov 8, 2018 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $26 → $28 | $8.13 | +244.40% | 2 | Aug 22, 2018 | |
| ALKS Alkermes | Initiates: Buy | $60 | $28.81 | +108.26% | 1 | Jun 6, 2018 | |
| EVOK Evoke Pharma | Reinstates: Buy | $1,440 | $2.56 | +56,150.00% | 2 | Oct 19, 2017 |
MediciNova
Mar 25, 2019
Assumes: Buy
Price Target: $22
Current: $1.30
Upside: +1,592.31%
Supernus Pharmaceuticals
Nov 12, 2018
Maintains: Buy
Price Target: $68 → $65
Current: $31.16
Upside: +108.60%
Jazz Pharmaceuticals
Nov 8, 2018
Maintains: Buy
Price Target: $219 → $190
Current: $106.90
Upside: +77.74%
Amneal Pharmaceuticals
Aug 22, 2018
Maintains: Buy
Price Target: $26 → $28
Current: $8.13
Upside: +244.40%
Alkermes
Jun 6, 2018
Initiates: Buy
Price Target: $60
Current: $28.81
Upside: +108.26%
Evoke Pharma
Oct 19, 2017
Reinstates: Buy
Price Target: $1,440
Current: $2.56
Upside: +56,150.00%